Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 2/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.40 |
| ▸ | MLNR | O43193 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.36 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 2/20 | 0.34 |
| ▸ | MMP9 | P14780 | 2/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.34 |
| ▸ | CSF1R | P07333 | 1/20 | 0.34 |
| ▸ | FABP1 | P07148 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2008430 | 0.86 | MEP1B (0.40) | PTGS2PTGS1LTB4RMMP2MMP9 | |
| SCHEMBL2013462 | 0.82 | LMNA (0.42) | LTB4RMMP2MMP9FABP1 | |
| SCHEMBL2004234 | 0.82 | MMP2 (0.50) | LTB4RMMP2MMP9FABP1 | |
| SCHEMBL2009361 | 0.82 | MEP1B (0.41) | PTGS2PTGS1MMP2MMP9 | |
| SCHEMBL1711624 | 0.81 | LGMN (0.43) | PTGS2PTGS1 | |
| SCHEMBL2009235 | 0.81 | ALDH1A1 (0.47) | KIF11LTB4R | |
| SCHEMBL2009256 | 0.80 | CA1 (0.51) | MMP2MMP9 | |
| SCHEMBL2009054 | 0.79 | CA2 (0.46) | MMP2MMP9 | |
| SCHEMBL2012396 | 0.78 | MEN1 (0.50) | — | |
| SCHEMBL2005594 | 0.77 | MMP2 (0.51) | LTB4RMMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964643-B2 | Biphenyl-4-sulfonic acid-(4-hydroxybutyl)-amide and derivatives; inhibits osteoclast survival, formation, and/or activity and/or inhibits bone resorption; osteoporosis, rheumatoid arthritis, cancer associated bone disease, Paget's disease, antiinflammatory, -carcinogenic agents; immunostimulants | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2011-06-21 | — | — | US | disclosed |
| EP-1756046-B1 | ARYL ALKYL SULFONAMIDES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE CONDITIONS | UNIV ABERDEEN (GB) | 2009-12-09 | — | — | EP | disclosed |
| US-20080119555-A1 | Aryl Alkyl Sulfonamides As Therapeutic Agents For The Treatment Of Bone Conditions | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2008-05-22 | — | — | US | disclosed |
| EP-1756046-A2 | ARYL ALKYL SULFONAMIDES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE CONDITIONS | The University Court of The University of Aberdeen (GB) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005118528-A2 | ARYL ALKYL SULFONAMIDES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE CONDITIONS | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119555-A1 | Aryl Alkyl Sulfonamides As Therapeutic Agents For The Treatment Of Bone Conditions | ARSA, CNKSR1, BCL9L | KIF11 4843/4885PTGS2 2205/4885PTGS1 1037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.